Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.
Recent comments
1 week 6 days ago
2 weeks 4 days ago
12 weeks 4 days ago
16 weeks 5 days ago
17 weeks 5 days ago
17 weeks 5 days ago
38 weeks 6 days ago
43 weeks 11 hours ago
44 weeks 4 days ago
44 weeks 5 days ago